This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

17 Apr 2012

Amgen to Acquire KAI Pharmaceuticals in $315M Deal

KAI Pharmaceuticals is to become a wholly owned subsidiary of Amgen.

Amgen is to acquire privately held pharmaceutical company KAI Pharmaceuticals in an agreement worth $315 million in cash.


The biotechnology pioneer will acquire worldwide rights - excluding Japan - to KAI's lead product candidate KAI-4169, which is currently being developed for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease who are on dialysis.


KAI's clinical development programme for the drug has already produced promising phase-IIa results and Amgen has provided a loan to enable phase-III planning to proceed prior to closing.


Steve James, president and chief executive officer of KAI, said: "

Related News